- |||||||||| lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
[VIRTUAL] POSTNATAL LPV/R EXPOSURE, GROWTH, AND NEUROPSYCHOLOGICAL OUTCOMES AT SCHOOL AGE ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_1337; At school age, children exposed to LPV/r and 3TC at birth for one year had comparable growth and neuropsychological outcomes without evidence of long-term side-effects of LPV/r. It provides reassuring data on clinical outcomes for all HIV-infected children treated with this antiretroviral in early life.
- |||||||||| lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
[VIRTUAL] METABOLITES, PRETERM LABOR, AND ANTIRETROVIRAL THERAPY ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_1330; In this exploratory study of HIV infected gravidas receiving ART, untargeted metabolomics identified perturbations in both steroid hormone metabolism and nucleotide/ amino acid metabolism that predict PTB. Untargeted metabolomics may be an effective strategy for identifying potential mechanisms of PTB associated with ART, and warrants further investigation.
- |||||||||| [VIRTUAL] SAFETY AND PHARMACOKINETICS OF INTRAVENOUS VRC01LS AND 10-1074 IN YOUNG CHILDREN ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_864;
Early-treated HIV+ children may be ideal candidates for use of broadly neutralizing monoclonal antibodies (bNAbs) as an alternative to antiretroviral treatment (ART), but pediatric bNAb data to date has been limited to subcutaneous administration of VRC01/LS during infancy...All children were receiving lopinavir/ritonavir, zidovudine, lamivudine (and one was also on abacavir)...For VRC01LS, an increased maintenance dose of at least 15mg/kg may be needed to achieve concentrations similar to adults when dosed monthly. For 10-1074, predicted adult concentrations were slightly exceeded with 30mg/kg monthly.
- |||||||||| interferon beta-1b / University of Hong Kong
Enrollment open: Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment (clinicaltrials.gov) - Feb 28, 2020 P2, N=70, Recruiting, ABC exposures were relatively high compared to older infants during the first 3 months of life but decreased rapidly as infants matured. Not yet recruiting --> Recruiting
- |||||||||| Trial completion date, Trial primary completion date: Antiretroviral Regime for Viral Eradication in Newborns (clinicaltrials.gov) - Feb 27, 2020
P4, N=600, Recruiting, Not yet recruiting --> Recruiting Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||||||||| lopinavir/ritonavir / Generic mfg.
Journal: Pharmacotherapeutics for the New Coronavirus Pneumonia (Pubmed Central) - Feb 15, 2020 Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.
- |||||||||| lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Journal: The Impact of Antiretroviral Therapy on Malaria Parasite Transmission. (Pubmed Central) - Feb 13, 2020 We show that the combination zidovudine + lamivudine + lopinavir/ritonavir (LPV/r), employed as first-line HIV treatment in the field, has a strong inhibitory activity on the sporogonic stages of P. berghei and that several non-nucleoside reverse transcriptase inhibitors (NNRTI) have a moderate effect on this stage of the parasite's life cycle. Our results expose the effect of current first-line ART on Plasmodium infection and identify potential alternative therapies for HIV/AIDS that might impact malaria transmission.
- |||||||||| Mycobutin (rifabutin) / Pfizer, Lupin
Trial completion, Trial completion date, Trial primary completion date: Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly (clinicaltrials.gov) - Feb 12, 2020 P2, N=40, Completed, Our results expose the effect of current first-line ART on Plasmodium infection and identify potential alternative therapies for HIV/AIDS that might impact malaria transmission. Active, not recruiting --> Completed | Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Sep 2019 --> Dec 2019
- |||||||||| lopinavir/ritonavir / Generic mfg.
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: Simplified Treatment of Anti-retrovirus in China (C-STAR) (clinicaltrials.gov) - Feb 5, 2020 P=N/A, N=600, Recruiting, Both abscesses resolved and no recurrence of anaemia was noted. Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||||||||| Enrollment closed, Trial primary completion date: RESIST-2: 2nd-line ART for HIV-2 Infection (clinicaltrials.gov) - Jan 22, 2020
P=N/A, N=150, Active, not recruiting, Recruiting --> Active, not recruiting | Trial completion date: Apr 2021 --> Jan 2021 | Trial primary completion date: Apr 2021 --> Jan 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2022 --> May 2020
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal, Real-World Evidence: Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China. (Pubmed Central) - Jan 12, 2020 The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; however, the real-world safety and efficacy remain unknown...This is the first real-world LPV/r-based second-line treatment study to cover such a large population in China. These results provide strong clinical evidence that LPV/r-based second-line ART is effective in increasing CD4T cell counts and viral suppression rates with tolerable side effects in HIV-infected adults in China in whom first-line treatment had failed.
|